Received Oct 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Shingrix late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 53-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose on 16 Oct 2021). On 05-DEC-2024, the patient received the 2nd dose of Shingrix. On 05-DEC-2024, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Shingrix late second dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK receipt date: 01-OCT-2025 The pharmacist asked how to proceed after a patient received a late second dose of Shingrix. Lot numbers and expiration dates of both doses unknown by the healthcare professional given that they were administered in another facility. The batch number was not provided upon follow- up with the reporter